In the present study, we used an animal model of acute dural nociceptive activation of the trigeminovascular system, which has been shown to represent a valid model to study migraine neurobiology and has reliably predicted clinical efficacy of many therapeutics, such as triptans.5,8 We determined the effects of intravenous administration of NPY in trigeminovascular nociceptive responses, relevant to headache, and dissected the relative contributions of specific NPY receptors. The gene discussed is NPY; the disease is migraine disorder.